{
  "protocolSection": {
    "outcomesModule": {
      "otherOutcomes": [
        {
          "measure": "Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Day 1 (Post-application) and Weeks 2, 4, 8, and 14",
          "description": "Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.\n\nScore 0 (clear): no erythema present\n\nScore 1 (mild): slight erythema\n\nScore 2 (moderate): definite erythema\n\nScore 3 (severe): marked, fiery erythema",
          "timeFrame": "Day 1 (Post-application) and Weeks 2, 4, 8, and 14"
        },
        {
          "measure": "Number of Participants With Erythema Score Based on Local Tolerability as Assessed by the Investigator at Week 12",
          "description": "Erythema score was evaluated by the investigator on a 0 to 3 scale with a lower score indicating lesser severity.\n\nScore 0 (clear): no erythema present\n\nScore 1 (mild): slight erythema\n\nScore 2 (moderate): definite erythema\n\nScore 3 (severe): marked, fiery erythema",
          "timeFrame": "Week 12"
        }
      ],
      "primaryOutcomes": [
        {
          "measure": "Change From Baseline in Total Lesion Count at Week 12",
          "description": "Total lesion count was the sum of counts of the following lesion types (face only): Papule - raised inflammatory lesions, <0.5 cm in diameter with no visible purulent material; Pustule - raised inflammatory lesions, <0.5 cm in diameter with visible purulent material; Nodule - any circumscribed, inflammatory mass â‰¥0.5 cm in diameter.",
          "timeFrame": "Baseline, Week 12"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "abc",
          "description": "Treatment responders were defined as participants who have either (1) 2 ordinal",
          "timeFrame": "Baseline, Week 12"
        },
        {
          "measure": "def",
          "description": "Papule - raised inflammatory lesions",
          "timeFrame": "Baseline; Weeks 2, 4, 8, and 12"
        },
        {
          "measure": "ghi",
          "description": "Pustule - raised inflammatory lesions",
          "timeFrame": "Baseline; Weeks 2, 4, 8, and 12"
        }
      ]
    }
  },
  "hasResults": true
}
